There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Cytek Biosciences (CTKB – Research Report), DENTSPLY SIRONA (XRAY – Research Report) and Gilead Sciences (GILD – Research Report) with bullish sentiments.
Cytek Biosciences (CTKB)
In a report issued on November 13, David Westenberg from Piper Sandler assigned a Buy rating to Cytek Biosciences, with a price target of $10.00. The company’s shares closed last Wednesday at $5.71.
According to TipRanks.com, Westenberg is a 1-star analyst with an average return of
Currently, the analyst consensus on Cytek Biosciences is a Strong Buy with an average price target of $9.75, representing a 78.2% upside. In a report issued on November 7, TD Cowen also reiterated a Buy rating on the stock with a $12.00 price target.
See today’s best-performing stocks on TipRanks >>
DENTSPLY SIRONA (XRAY)
Jefferies analyst Brandon Couillard maintained a Buy rating on DENTSPLY SIRONA yesterday and set a price target of $36.00. The company’s shares closed last Wednesday at $29.32.
According to TipRanks.com, Couillard is a top 100 analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for DENTSPLY SIRONA with a $34.18 average price target, which is a 18.7% upside from current levels. In a report released today, Needham also initiated coverage with a Buy rating on the stock with a $35.00 price target.
Gilead Sciences (GILD)
Jefferies analyst Michael Yee maintained a Buy rating on Gilead Sciences yesterday and set a price target of $95.00. The company’s shares closed last Wednesday at $75.04, close to its 52-week low of $72.87.
According to TipRanks.com, Yee is a 4-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Gilead Sciences with a $89.88 average price target, a 21.1% upside from current levels. In a report issued on November 7, TD Cowen also maintained a Buy rating on the stock with a $95.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on CTKB:
- Cytek® Aurora™ CS System Wins BioTech Breakthrough Award for ‘Cell Sorting Product of the Year’
- Cytek Biosciences price target lowered to $8 from $13 at Morgan Stanley
- Cytek Biosciences price target lowered to $10 from $15 at Piper Sandler
- Cytek Biosciences achieves ISO 13485 Certification at headquarters
- Cytek® Biosciences Achieves ISO 13485 Certification at Headquarters
